Key result
Left atrial appendage closure with the Amplatzer Cardiac Plug provided similar long-term efficacy to the Amulet occluder.
Why the study?
The Amulet was designed to improve clinical outcomes of the first-generation Amplatzer Cardiac Plug, but long-term comparative clinical outcomes remained to be evaluated.
Does the second-generation Amulet occluder improve long-term efficacy and safety compared to the first-generation Amplatzer Cardiac Plug in patients undergoing left atrial appendage closure?
Cohort (n=1,415)
Yes
Does the second-generation Amulet occluder improve long-term efficacy and safety compared to the first-generation Amplatzer Cardiac Plug in patients undergoing left atrial appendage closure?
Answers are grounded in this paper and cite their sources.
First and second-generation Amplatzer devices for left atrial appendage closure provide similar long-term efficacy, safety, and net clinical benefit.
OBJECTIVES: To compare long-term clinical outcomes after left atrial appendage closure with the Amplatzer Cardiac Plug (ACP) and Amulet. BACKGROUND: The Amulet was designed to improve clinical outcomes of first-generation ACP. METHODS: Three Amplatzer registries (Bern, Coburg, Zurich), with enrollment of patients from 2009 to 2018, were retrospectively analyzed. The primary safety endpoint was a composite of major peri-procedural complications and major bleedings, the primary efficacy endpoint included stroke, systemic embolism, and cardiovascular/unexplained death. The net clinical benefit was a combination of all above-mentioned hazards. RESULTS: -VASc score 4.4 ± 1.6 vs. 4.6 ± 1.7), and bleeding risk (HAS-BLED score 3.2 ± 1.1 vs. 3.2 ± 0.9) were comparable. The primary endpoints of efficacy (72/998, 7.2% [ACP] vs. 43/417, 10.3% [Amulet]; hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.44-1.02, p = .062), safety (40/998, 4.0% vs. 18/417, 4.3%; HR, 1.15; 95% CI, 0.53-2.51, p = .72), and the net clinical benefit (101/998, 10.1% vs. 55/417, 13.4%; HR, 0.73; 95% CI, 0.49-1.07, p = .11) were similar. CONCLUSION: In the long term, left atrial appendage closure with first and second-generation Amplatzer devices provided similar efficacy, safety, and net clinical benefit. Clinical outcomes may be rather determined by implantation technique and hemodynamics, but not by the design modifications of the Amulet.
No takes yet. Share an insight, caveat, or question.
Kleinecke et al. (2019) conducted a cohort in Left atrial appendage closure (n=1,415). Amplatzer Cardiac Plug (ACP) vs. Amulet occluder was evaluated on Stroke, systemic embolism, and cardiovascular/unexplained death (HR 0.67, 95% CI 0.44-1.02, p=0.062). Left atrial appendage closure with the Amplatzer Cardiac Plug provided similar long-term efficacy to the Amulet occluder.
Synapse has enriched 10 related papers. Consider them for comparative context: